Call Options on GILD on 6/24/2024

Gilead Sciences, Inc. (GILD), a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.

The company was incorporated in 1987 and is headquartered in Foster City, California.

We will be trading July 12th Call Options.

Last Trade: $70.67

Trading Range: $62.07 - $87.87

Trade Buy 1 July $75.00 Call at $0.44 For a net debit of $0.44 Profit/Loss Analysis Breakeven at $75.44 Maximum profit is unbounded Maximum loss is ($44.00) at strike of $75.00 Closing Summary Sold 1 July $75.00 Call at $0.00

Position closed on 7/17/2024 at price of $0.00 with a -100.00% loss in 23 days.

Back to Portfolio